SCHEDULE 8Consequential provision
PART 1Amendment of primary legislation
Amendment of the Access to Medical Treatments (Innovation) Act 2016I12
In section 3(2)(b) and (4)(a), (b) and (c) of the Access to Medical Treatments (Innovation) Act 2016 M1 (provision supplementary to section 2: database of innovative treatments) insert “
UK
”
before “marketing authorisation”.